- External exposure doses were estimated from activity records over four months following the nuclear accident for 2,055,238residents in the prefecture as of 11 Mar. 2011.
- Out of the 467,484people (as of the end of March 2024) who responded to the survey excluding those with experience in radiation work and those whose estimated exposure period was less than four months, 99.8% were exposed to less than 5 mSv (millisieverts), with the maximum value being 25 mSv.
*Total number of respondents: 569,691 (response rate: 27.7%)
- The dose estimates obtained in this survey (external effective dose for the first 4 months after the accident: 99.8% less than 5mSv, etc.) have been evaluated as being below the level of statistically significant differences in verifiable health effects in the light of current scientific knowledge.
- See here for more on the survey results
Document 1 from the 52nd "Prefectural Oversight Committee for the Fukushima Health Management Survey" ( 2 August 2024) (Japanese only)
1 Preliminary baseline screening (As of March 31, 2018) [Conducted in FY2011-2013]
Primary Examination (Completed on 30 Apr. 2015)
Number of eligible individuals |
367,637 people |
Number of examinees |
300,472 people (Examination rate: 81.7%) |
Number of results acquired |
300,472 people (Aquisition rate: 100.0%) |
A (A1) classification |
154,605 people (51.5%) |
A (A2) classification |
143,573 people (47.8%) |
B classification |
2,293 people (0.8%) |
C classification |
1 person (0.0%) |
Confirmatory Examination (As of 31 Mar. 2018)
Number of eligible individuals |
2,293 people |
Number of examinees |
2,130 people(Examination rate: 92.9%) |
Number of confirmed diagnosis |
2,091 people (Diagnose rate: 98.2%)
Of which, cases with malignancy or suspected malignancy: 116 people |
2 Full scale examination (Second round examination) (As of 31 Mar. 2021) [Conducted in FY2014-2015]
Primary Examination
Number of eligible individuals |
381,237 people |
Number of examinees |
270,552 people(Examination rate: 71.0%) |
Number of results acquired |
270,552 people(Aquisition rate: 100.0%) |
A (A1) classification |
108,726 people (40.2%) |
A (A2) classification |
159,596 people (59.0%) |
B classification |
2,230 people (0.8%) |
C classification |
0 people (0.0%) |
Confirmatory Examination
Number of eligible individuals |
2,230 people |
Number of examinees |
1,877 people (Examination rate: 84.2%) |
Number of confirmed diagnosis |
1,834 people (Diagnose rate: 97.7%)
Of which, cases with malignancy or suspected malignancy: 71 people |
3 Full Scale Examination (Third round examination) (As of 31 Mar. 2021) [Conducted in FY2016-2017]
Primary Examination
Number of eligible individuals |
336,667 people (Excluding individuals born in FY1992-1993, the subjects of the milestone examination at the age of 25) |
Number of examinees |
217,922 people (Examination rate: 64.7%) |
Number of results acquired |
217,922 people (Aquisition rate: 100.0%) |
Confirmatory Examination
Number of eligible individuals |
1,502 people |
Number of examinees |
1,104 people (Examination rate: 73.5%) |
Number of confirmed diagnosis |
1,068 people (Diagnose rate: 96.7%)
Of which, cases with malignancy or suspected malignancy: 31 people |
4 Full Scale Examination (Fourth round examination) (As of 30 Jun. 2022) [Conducted in FY2018-2019]
Primary Examination
Number of eligible individuals |
294,228 people (Excluding individuals born in FY1992-1995, the subjects of the milestone examination at the age of 25) |
Number of examinees |
183,410 people (Examination rate: 62.3%) |
Number of results acquired |
183,410 people (Aquisition rate: 100.0%) |
A (A1) classification |
61,712 people (33.6%) |
A (A2) classification |
120,304 people (65.6%) |
B classification |
1,394 people (0.8%) |
C classification |
0 people (0.0%) |
Confirmatory Examination
Number of eligible individuals |
1,394 people |
Number of examinees |
1,036 people (Examination rate: 74.3%) |
Number of confirmed diagnosis |
1,016 people (Diagnose rate: 98.1%)
Of which, cases with malignancy or suspected malignancy: 39 people |
5 Full Scale Examination (Fifth round examination) (As of 31 Dec. 2023) [Conducted in FY2020-2022]
Primary Examination
Number of eligible individuals |
252,938 people (Excluding individuals born in FY1992-1997, subjects of the milestone examination) |
Number of examinees |
113,950 people (Examination rate: 45.1%)
|
Number of results acquired |
113,946 people (Aquisition rate: 100.0%) |
A (A1) classification |
32,843 people (28.8%) |
A (A2) classification |
79,757 people (70.0%) |
B classification |
1,346 people (1.2%) |
C classification |
0 people (0.0%) |
Confirmatory Examination
Number of eligible individuals |
1,346 people |
Number of examinees |
1,092 people (Examination rate: 81.1%) |
Number of confirmed diagnosis |
1,058 people (Diagnose rate: 96.9%)
Of which, cases with malignancy or suspected malignancy: 45 people |
6 Full Scale Examination (Sixth round examination) (As of 31 Dec. 2023) [Conducted in FY2023-2024]
Primary Examination
Number of eligible individuals |
211,885 people (Excluding individuals born in FY1992-1999, subjects of the milestone examination) |
Number of examinees |
34,435 people (Examination rate: 16.3%)
|
Number of results acquired |
27,923 people (Aquisition rate: 81.1%) |
A (A1) classification |
7,601 people (27.2%) |
A (A2) classification |
19,940 people (71.4%) |
B classification |
382 people (1.4%) |
C classification |
0 people(0.0%) |
7 Milestone Examination at the age of 25 (As of 30 Sep. 2023) [Conducted in FY2017 onwards]
Primary Examination
Number of eligible individuals |
129,006 people (Born in FY1992-1997) |
Number of examinees |
11,867 people (Examination rate: 9.2%) |
Number of results acquired |
11,858 people (Aquisition rate: 99.9%) |
A (A1) classification |
5,039 people (42.5%) |
A (A2) classification |
6,172 people (52.0%) |
B classification |
647 people (5.5%) |
C classification |
0 people (0.0%) |
Confirmatory Examination
Number of eligible individuals |
647 people |
Number of examinees |
545 people (Examination rate: 84.2%) |
Number of confirmed diagnosis |
535 people (Diagnose rate: 98.2%)
Of which, cases with malignancy or suspected malignancy: 23 people |
8 Milestone examination at age 30 (As of 30 Sep. 2023) [Conducted in FY2022 onwards]
Primary Examination
Number of eligible individuals |
22,625 people (Born in FY1992) |
Number of examinees |
1,571 people (Examination rate: 6.9%) |
Number of results acquired |
1,562 people (Aquisition rate: 99.4%) |
A (A1) classification |
696 people (44.6%) |
A (A2) classification |
732 people (46.9%) |
B classification |
134 people (8.6%) |
C classification |
0 people (0.0%) |
Confirmatory Examination
Number of eligible individuals |
134 people |
Number of examinees |
107 people (Examination rate: 79.9%) |
Number of confirmed diagnosis |
96 people (Diagnose rate: 89.7%)
Of which, cases with malignancy or suspected malignancy: 5 people |
*Those who receive a B or C in the primary examination are invited to undergo a confirmatory examination.
Results of FY 2022
|
Number of eligible individuals |
Number of examinees |
Examination rate |
For those aged 15 and below |
18,253 people |
1,704 people |
9.3% |
For those aged 16 and above |
193,195 people |
34,269 people |
17.7% |
Overall |
211,448 people |
35,973 people |
17.0% |
Results of FY 2021
Number of eligible individuals |
Number of valid responses |
Response rate |
196,569 people |
40,749 people |
20.7% |
- The survey was conducted to understand the mental and physical health of pregnant and postpartum women, reduce anxiety, and provide necessary care.
- The survey consists of a "Main Survey" conducted about one year after a pregnancy notification has been submitted and "Follow-up Surveys" conducted four and eight years after childbirth.
- The Main Survey ended in FY2022 because the rates of premature birth, low birth weight, and congenital anomalies were found to be almost no different from government statistics and generally reported data.
- For more detailed results of the survey, please see the link below.
About Fukushima Health Management Survey "Pregnancy and Birth Survey" (Japanese only)
The examination measures the radioactive cesium absorbed into the body from the atmosphere, food and other sources using a whole-body counter, and estimates the radiation dose expected to be received over a lifetime.
Fukushima Health Management Survey Investigative Committee
For Fukushima Health Management Survey, an investigative committee consisting of experts has been established for professional insight.
For the latest survey status of the Fukushima Health Management Survey, please refer to the materials of Investigative Commitee at the links below.
Fukushima Health Management Survey Investigative Committee (Japanese Only)
PDF形式のファイルをご覧いただく場合には、Adobe社が提供するAdobe Readerが必要です。
Adobe Readerをお持ちでない方は、バナーのリンク先からダウンロードしてください。(無料)